Dysbiosis and Gut Microbiota Modulation in Systemic Sclerosis

J Clin Rheumatol. 2022 Mar 1;28(2):e568-e573. doi: 10.1097/RHU.0000000000001748.

Abstract

Gastrointestinal (GI) involvement is an early manifestation in systemic sclerosis (SSc), affecting more than 90% of patients, and severe GI disease is a marker of poor prognosis and mortality. Recent studies have hypothesized that alterations of the intestinal microbiota, known as dysbiosis, may represent 1 of the possible environmental factors influencing SSc disease status. In addition, specific microorganisms may be associated with SSc pathogenesis, progression, and GI manifestations. Therapeutic approaches aiming to modulate the intestinal microbiota have emerged, as alternatives to treat GI symptoms, and dietary interventions, probiotic administration, and fecal microbiota transplantation are potential therapies for SSc patients. However, given the complexity and variability of pathogenesis and clinical manifestations in SSc, these therapies need to be combined with additional interventions that target other disease components. Here, we summarize studies addressing intestinal dysbiosis in SSc and discuss the potential of microbiota modulators to treat SSc-related GI disorders.

Trial registration: ClinicalTrials.gov NCT04627727.

MeSH terms

  • Dysbiosis / complications
  • Dysbiosis / therapy
  • Gastrointestinal Diseases* / diagnosis
  • Gastrointestinal Diseases* / etiology
  • Gastrointestinal Diseases* / therapy
  • Gastrointestinal Microbiome*
  • Humans
  • Scleroderma, Systemic* / complications
  • Scleroderma, Systemic* / diagnosis
  • Scleroderma, Systemic* / therapy

Associated data

  • ClinicalTrials.gov/NCT04627727